Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.52 |
| ▸ | GABRE | P78334 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493736 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL11964237 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL242069 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL1260777 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL1072831 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL25212375 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL10188550 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL11964239 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL304519 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL12491655 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637728-A1 | COMPOSITION | BioNTech Delivery Technologies GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| WO-2024133635-A1 | COMPOSITION | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| CN-114105911-B | Preparation method for co-production of cyclododecene ether and cyclododecanol | 中国天辰工程有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-112830874-A | Preparation method of oil-soluble molybdenum carboxylate | 洛阳康纳森新能源科技有限公司 | 2021-05-25 | — | — | CN | claimed |
| CN-112679547-A | Preparation method of oil-soluble carboxylic acid complex | 洛阳康纳森新能源科技有限公司 | 2021-04-20 | — | — | CN | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| CN-1946404-A | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-04-11 | — | — | CN | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | claimed |
| US-5179193-A | From dihaloaromatic sulfone, polyhalodiarylsulfone and polymerizable sulfur source; coatings, films, moldings, fibers | PHILLIPS PETROLEUM COMPANY (US) | 1993-01-12 | — | — | US | claimed |
| US-5177174-A | Branched aromatic sulfide/sulfone polymer production | PHILLIPS PETROLEUM COMPANY (US) | 1993-01-05 | — | — | US | claimed |
| US-4647661-A | Method of preparing ω-lactams, in particular caprolactam | CHIMICA DEL FRIULI S.P.A. (IT) | 1987-03-03 | — | — | US | claimed |
| EP-0197408-A2 | A method of preparing omega -lactams, in particular caprolactam | CHIMICA DEL FRIULI S.p.A. (IT) | 1986-10-15 | — | — | EP | claimed |
| US-3978120-A | METHOD FOR THE PRODUCTION OF ALICYCLIC ANHYDRIDES | SNIA VISCOSA SOCIETA NAZIONALE INDUSTRIA APPLICAZIONI VISCOSA S.P.A. (IT) | 1976-08-31 | — | — | US | claimed |
| US-3941822-A | Process for the preparation of methylene-bridged diaryl isocyanates | OLIN CORPORATION (US) | 1976-03-02 | — | — | US | claimed |
| US-3932484-A | FROM CYCLODODECATRIENE AND CARBON MONOXIDE, COORDINATION CATALYST | TEXACO INC. (US) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | CES2 818/4885CES1 3644/4885TSHR 4144/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CES2 818/4885CES1 3644/4885TSHR 4144/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CES2 818/4885CES1 3644/4885TSHR 4144/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CES2 818/4885CES1 3644/4885TSHR 4144/4885 |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | PDE12, PDE3A, PDE2A | CES2 1415/4885CES1 2400/4885TSHR 3371/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | CES2 818/4885CES1 3644/4885TSHR 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.